Seeking Alpha EN

Arcutis Biotherapeutics GAAP EPS of $0.13 beats by $0.03, revenue of $129.5M beats by $16.47M

Feb 25, 2026 &02012525202628; 21:01 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +80/100

High impact Short-term (days)

WHAT THIS MEANS

Arcutis Biotherapeutics ha superato le aspettative con un EPS GAAP di $0.13 e un fatturato di $129,5 milioni, superando le previsioni di $0.03 e $16,47 milioni rispettivamente.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

ACUT.MI

ACUT.MIStock

Expected to rise

Risultati finanziari superiori alle aspettative

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Considere l'acquisto di Arcutis Biotherapeutics (ACUT.MI) per breve termine, in base ai risultati finanziari positivi e al superamento delle aspettative.

KEY SIGNALS

Risultati finanziari positiviSuperamento delle aspettative

SECTORS INVOLVED

Biotecnologie

Analysis generated on Feb 26, 2026 at 05:20 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Arcutis Biotherapeutics GAAP EPS of $0.13 beats by $0.03, revenue of $129.5M beats by $16.47M

RELATED INTELLIGENCE